EPL Clinical Pathology Evaluation and Consultation Services
Experimental Pathology Laboratories, Inc. (EPL) is pleased to announce that Dr. Valerie Barlow will be providing clinical pathology evaluation and consultation services for EPL.
Dr. Valerie G. Barlow holds a DVM, a Master of Science and Ph.D., and is a Diplomate of the American College of Veterinary Pathologists (clinical pathology). Dr. Barlow was born and raised in France where she attended the Ecole Nationale Vétérinaire de Toulouse for her Doctorate of Veterinary Medicine. While in veterinary school, she completed a Master of Science in Parasitology at the University Paul Sabatier of Toulouse and worked as a relief veterinarian. Upon completion of her DVM, she was accepted in a combined clinical pathology and residency program at Colorado State University which was sponsored by Rhone Poulenc Rorer, a Sanofi legacy company. At Colorado State, she worked in an immunology laboratory focusing on the immune response to Leishmania major infection, evaluating the effects of maxadilan (a small peptide from the salivary gland of a mosquito vector of the disease) on hematopoiesis. After completing her PhD, she went back to France to work as a Clinical Pathologist and Laboratory Manager at Aventis, a Sanofi legacy company.
After five years in France, she was transferred to Malvern, Pennsylvania where she oversaw two Sanofi clinical pathology laboratories. She was also in charge of harmonizing the seven Sanofi global clinical pathology laboratory sites to ensure consistent processes and results across studies and programs. She was transferred to the New Jersey site and started a biomarker laboratory to support both discovery and clinical activities while still maintaining her clinical pathology duties. As Sanofi reorganized its Massachusetts R&D organization, she was transferred to Genzyme (a Sanofi company) to join a newly formed Translational Medicine group. Her responsibilities included managing a biomarker assay development group, providing comprehensive translational support for projects, coordinating biomarker development processes for the Translational Medicine Unit, and providing clinical pathology support for the Disposition, Safety and Animal Research Scientific Core Platform.
Throughout her career, Dr. Barlow has been involved with biomarkers including preclinical safety biomarkers, clinical biomarkers, assay development and sample analysis under GLP conditions. She was a Sanofi representative for C-Path and the FNIH Biomarker Consortium and the New Biomarker Development Alliance (NBDA).
Prior to her move to Massachusetts, she was an Adjunct Professor at the University of Pennsylvania School of Veterinary Medicine. Recently, she left Genzyme to move with her family back to Pennsylvania and established a consulting company specializing in clinical pathology services. She likes to spend her free time with family, driving her rambunctious 6-year-old boy to hockey practices and games and other sport activities, and trying new recipes with friends.